These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 9276200

  • 41. Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.
    Altmann V, Schumacher-Schuh AF, Rieck M, Callegari-Jacques SM, Rieder CR, Hutz MH.
    Pharmacogenomics; 2016 Apr; 17(5):481-8. PubMed ID: 27019953
    [Abstract] [Full Text] [Related]

  • 42. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment.
    Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, Vives F.
    Mov Disord; 2010 Mar 15; 25(4):489-93. PubMed ID: 20063406
    [Abstract] [Full Text] [Related]

  • 43. Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa.
    Pal PK, Sathyaprabha TN, Tuhina P, Thennarasu K.
    Mov Disord; 2007 Feb 15; 22(3):420-4. PubMed ID: 17230476
    [Abstract] [Full Text] [Related]

  • 44. A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation.
    Markopoulou K, Wszolek ZK, Pfeiffer RF.
    Ann Neurol; 1995 Sep 15; 38(3):373-8. PubMed ID: 7668822
    [Abstract] [Full Text] [Related]

  • 45. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A, Molinari SP, Kollmeier B, Yahr MD.
    Adv Neurol; 1996 Sep 15; 69():3-11. PubMed ID: 8615142
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Does thalamotomy alter the course of Parkinson's disease?
    Tasker RR, DeCarvalho GC, Li CS, Kestle JR.
    Adv Neurol; 1996 Sep 15; 69():563-83. PubMed ID: 8615182
    [No Abstract] [Full Text] [Related]

  • 51. Levodopa therapy for Parkinson's disease: challenges and future prospects.
    Olanow CW, Lees A, Obeso J.
    Mov Disord; 2008 Sep 15; 23 Suppl 3():S495-6. PubMed ID: 18781670
    [No Abstract] [Full Text] [Related]

  • 52. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).
    Morrison CE, Borod JC, Brin MF, Hälbig TD, Olanow CW.
    J Neural Transm (Vienna); 2004 Oct 15; 111(10-11):1333-41. PubMed ID: 15480842
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Levodopa fractionation in Parkinson's disease.
    Nyholm D, Stepien V.
    J Parkinsons Dis; 2014 Oct 15; 4(1):89-96. PubMed ID: 24398654
    [Abstract] [Full Text] [Related]

  • 55. Prosody and levodopa in Parkinson's disease.
    Azevedo LL, Reis CA, Souza IS, Cardoso FE.
    Arq Neuropsiquiatr; 2013 Nov 15; 71(11):835-40. PubMed ID: 24394867
    [Abstract] [Full Text] [Related]

  • 56. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
    De Reuck J, De Weweire M, Van Maele G, Santens P.
    J Neurol Sci; 2005 Apr 15; 231(1-2):35-9. PubMed ID: 15792818
    [Abstract] [Full Text] [Related]

  • 57. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
    Bachmann CG, Zapf A, Brunner E, Trenkwalder C.
    Eur J Neurol; 2009 Aug 15; 16(8):895-901. PubMed ID: 19374662
    [Abstract] [Full Text] [Related]

  • 58. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 15; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 59. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K, Tiamkao S, Pongchaiyakul C, Pulkes T.
    J Med Assoc Thai; 2006 May 15; 89(5):632-7. PubMed ID: 16756048
    [Abstract] [Full Text] [Related]

  • 60. [Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital].
    Santos-García D, Macías M, Llaneza M, Fuster-Sanjurjo L, Echarri-Piudo A, Belmonte S, Blanco S.
    Neurologia; 2010 May 15; 25(9):536-43. PubMed ID: 21093702
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.